Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

被引：0
|
作者：
Elegbede, A. [1 ]
Ezeife, D. [2 ]
Gibson, A. [1 ]
Dean, M. [1 ]
Petersen, L. [1 ]
Bebb, G. [1 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Brain metastasis; Gender; KRAS mutant NSCLC survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P59.25
引用
收藏
页码：S1159 / S1160
页数：3
相关论文
共 50 条
  • [21] AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Fukui, Sarina
    Sawada, Ryo
    Tachibana, Yusuke
    Matsui, Yohei
    Nakamura, Ryota
    Ishida, Masaki
    Kawachi, Hayato
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Furuya, Naoki
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Nishioka, Naoya
    Horinaka, Mano
    Sakai, Toshiyuki
    Uehara, Hisanori
    Yano, Seiji
    Son, Bo-Kyung
    Tokuda, Shinsaku
    Takayama, Koichi
    CANCER LETTERS, 2024, 587
  • [22] Dual RAF/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants
    Coma, S.
    Chowdhury, S.
    Musteanu, M.
    Stewart, A.
    Pickard, L.
    Krebs, M.
    Minchom, A.
    Banerji, U.
    Barbacid, M.
    Pachter, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1124 - S1124
  • [23] The Emerging Role of KRAS G12C Inhibitors in the Treatment of Locally Advanced or Metastatic Colorectal Cancer
    Ciombor, Kristen
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (08) : 503 - 505
  • [24] In Response to "De Novo KRAS G12C Mutant SCLC: A Case Report"-
    Balbach, Meridith L.
    Eisenberg, Rosana
    Iams, Wade T.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [25] Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
    Girard, N.
    Perol, M.
    Debieuvre, D.
    Bosquet, L.
    Veillard, C.
    Caillon, M.
    Tzala, L.
    Desamericq, G.
    Valette, C. Audigier
    ANNALS OF ONCOLOGY, 2023, 34
  • [26] KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
    Mohn, Deanna
    Saiki, Anne Y.
    Achanta, Pragathi
    Stapper, Andres Plata
    Lipford, J. Russell
    Verma, Rati
    CANCER RESEARCH, 2023, 83 (07)
  • [27] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [28] Characteristics and Treatment Sequences of Patients with KRAS G12C, Other KRAS and KRAS-Wild-Type Advanced or Metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME Cohort
    Girard, Nicolas
    Perol, Maurice
    Debieuvre, Didier
    Lemonnier, Lydie
    Veillard, Charlotte
    Caillon, Megane
    Tzala, Lia
    Desamericq, Gaelle
    Audigier-Valette, Clarisse
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 342 - 342
  • [29] The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study
    Matsubara, Y.
    Masuishi, T.
    Fushiki, K.
    Sawada, K.
    Chida, K.
    Kumanishi, R.
    Shirasu, H.
    Kawamoto, Y.
    Kotani, D.
    Kato, K.
    Kawakami, T.
    Yuki, S.
    Yamazaki, K.
    Komatsu, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S208 - S208
  • [30] Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation
    Aparicio, Jorge
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
12345